gefitinib has been researched along with dalteparin in 1 studies
Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (dalteparin) | Trials (dalteparin) | Recent Studies (post-2010) (dalteparin) |
---|---|---|---|---|---|
5,231 | 566 | 2,919 | 5,665 | 1,423 | 2,267 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Duan, J; Fan, J; Fan, S; Li, X; Pan, Y; Wang, Y; Xiaokaiti, Y; Yang, H; Yuan, L | 1 |
1 other study(ies) available for gefitinib and dalteparin
Article | Year |
---|---|
Enoxaparin sensitizes human non-small-cell lung carcinomas to gefitinib by inhibiting DOCK1 expression, vimentin phosphorylation, and Akt activation.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Enoxaparin; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; rac GTP-Binding Proteins; Vimentin; Xenograft Model Antitumor Assays | 2015 |